摘要
目的评价阿莫西林-克拉维酸钾序贯治疗儿童急性下呼吸道感染(ALRI)的有效性、安全性和药物经济学意义.方法选择212例ALRI患儿,随机分为序贯治疗组和对照组各106例,序贯治疗组先给予阿莫西林-克拉维酸钾注射液静滴3～5 d,待病情稳定和缓解后改为阿莫西林-克拉维酸钾片剂口服5～9 d;对照组给予阿莫西林-克拉维酸钾注射液静滴7～14 d.两组的其余对症治疗相同.结果两组的平均疗程(d)、痊愈率、总有效率和不良反应差异无统计学意义(P>0.05),而平均住院时间(d)、医疗成本,序贯治疗组则比对照组减少,差异有统计学意义(P<0.001).在总有效率大致相同的情况下,对照组的总有效率每增加1个百分点费用需增加32.99元,序贯治疗组仅增加22.15元.结论阿莫西林-克拉维酸钾序贯治疗儿童ALRI临床疗效确切、安全和经济方便,值得临床推广应用.
Objective To evaluate the efficacy,security and pharmcoeconomics of amoxicillin-clavulanate potassium sequential therapy in treating children with acute lower respiratory tract infection(ALRI).Methods 212 patients with ALRI were randomly divided into two groups ,sequential therapy group and control group. Patients in sequential therapy group were treated at first with amoxicillin-clavulanate potassium intravenous drip for 3～5 d then with oral amoxicillin-clavulanate potassium for 5～9 d,while the control group was treated with amoxicillin-clavulanate potassium intravenous drip for 7～14 d.Results There were no significant difference in mean recovery time,recovery rate,total effective rate and incidence of adverse reaction between the two groups.But the mean hospitalization time and total cost in sequential therapy group were significantly less than those in control group.Conclusion The effect of amoxicillin-clavulanate potassium sequential therapy in treating children with ALRI is certain,safe and economic,it is valuable in clinical application.
出处
《广西医学》
CAS
2005年第4期506-508,共3页
Guangxi Medical Journal
关键词
阿莫西林-克拉维酸钾
急性下呼吸道感染
儿童
序贯治疗
成本-效果分析
Amoxicillin-clavulanate potassium
Acute lower respiratory tract infection
Children
Sequential therapy
Cost-effect analysis
